In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline
14 July, 2005 by Staff WritersChris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO.
Avexa CEO: how we landed Shire deal
13 July, 2005 by Ruth BeranWhen asked about Avexa's (ASX:AVX) successful in-licensing of HIV drug AVX754 from UK company Shire Pharmaceuticals, Avexa's CEO, Julian Chick, likes to use the following anonymous quote: "How did a little Australian company with no proven ability in-license a phase II drug from a specialty pharma?"
GE sale offers new hope to Iatia
12 July, 2005 by Helen SchullerPhase imaging enhancement specialist Iatia (ASX:IAT) is showing the early stages of a turnaround following the signing of two deals within the last month.
The Burrill view: Get ready for biotech's next phase
07 July, 2005 by Iain ScottSteven Burrill's 'state of the industry' address is the star turn at the annual BIO conference in the US. Iain Scott was in the audience for this year's words of wisdom.
Q3 dragged down local biotech in 04/05: Intersuisse
05 July, 2005 by Helen SchullerA lacklustre third quarter for Australian biotechnology stocks resulted in an overall fall of almost 20 per cent for the year ending June 2005, according to the Intersuisse Biotechnology Index.
Australasian mentorship for biotech entrepreneurs
24 June, 2005 by Ruth BeranSpeaking at BIO 2005 in Philadelphia, Victorian innovation minister John Brumby has announced the roll out of the state government's Biotechnology Entrepreneur Program across Australia and New Zealand.
Venture capital investment earmarked for South Australian bioscience
23 June, 2005 by Susan WilliamsonA major venture capital investment of tens of millions of dollars is currently being secured for the South Australian bioscience industry.
Looking ahead
22 June, 2005 by Graeme O'NeillPeter Beattie talks to Graeme O'Neill about his vision of the future for Queensland bioscience.
States of the nation
22 June, 2005 by Cristy BurneState government policy has been vital in helping to shape the Australian biotechnology industry. Here, Cristy Burne takes us for a tour of Western Australia, the state that later this year will host the national biotech conference.
Australian biotechs partner far and wide
22 June, 2005 by Michael VitaleThere's no tyranny in distance for some globetrotting Australian biotechnology companies, writes Michael Vitale
Bio21: The co-op for science commerce
22 June, 2005 by Anne FletcherOpened by the Victorian premier earlier this month, the Bio21 Institute provides a structure in which research, business incubation and commercialisation are all conducted under one collaborative roof, Anne Fletcher reports.
Transforming technology
22 June, 2005 by Susan WilliamsonThe nanotech sector in Australia is growing with potential.
In Brief: SciGen, Institute of Drug Technology, Phosphagenics
21 June, 2005 by Ruth BeranSciGen (ASX:SIE) has executed a commercialisation agreement with Rangs Pharmaceuticals for the commercialisation of insulin in Bangladesh.
Baker Institute spin-off enters agreement
20 June, 2005 by Susan WilliamsonV-Kardia, the first spin-off company from the Baker Heart Research Institute in Melbourne, has entered into an agreement with Californian-based molecular cardiology company, Celladon, to develop and supply its V-Focus device for percutaneous delivery of gene therapy for congestive heart failure.
Taskforce to advise government on investment in medical research
20 June, 2005 by Susan WilliamsonThe federal government has set up the Private Sector Investment Taskforce to come up with strategies to gain more support for Australian researchers from business and philanthropic funds, both in Australia and overseas.
